biostudies-literatureUnknown332(7)HARMONi-A Study Investigators<h4>Importance</h4>For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.<h4>Objective</h4>To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled.<h4>Interventions</h4>Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed andJAMA561-570https://www.ebi.ac.uk/biostudies/studies/S-EPMC11337070biostudies-literatureIvonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.PMC11337070Hu YLiang WDong XHuang JGuo YDu XWu DZhang LSu HGuo JXia MChen YWang YWang ZYang HYang LYang KChen LHe MLu DXu FChen HLi KSun YLi MLi WLi XFeng JHe ZLu HHARMONi-A Study InvestigatorsLu JHu MXu SFeng WYang RLan HLiu LHou XJia LZhao YYi TCheng YLiu XWang ZMSong QJia YLi BSong XZhao HZhou JZhou MZhou NFan YLv DHuang YZhang ZFang WZhang YLuo YLiu BLiu CPeng JfalseIvonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.<h4>Importance</h4>For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.<h4>Objective</h4>To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled.<h4>Interventions</h4>Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed and2024-01-01T00:00:00Z2024 Aug2026-07-15T08:07:11.442Z2025-04-06T22:26:00.949ZS-EPMC113370703882054910.1001/jama.2024.10613